PWP
REGN icon

Private Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Private Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Sell
360
-1,735
-83% -$1.18M 0.02% 167
2026
Q1 		$1.62M Sell
2,095
-175
-8% -$134K 0.12% 78
2025
Q4 		$1.75M Buy
+2,270
New +$1.54M 0.12% 74
2016
Q4 		– Sell
-500
Closed -$201K – 120
2016
Q3 		$201K Buy
+500
New +$201K 0.05% 115

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Private Wealth Partners's REGN Position: Q2 2026 in Review

Private Wealth Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 83% in Q2 2026, selling an estimated $1.18M and leaving 360 shares worth $224K. The position accounts for 0.02% of the portfolio, ranked #167.

Private Wealth Partners first reported a position in REGN in Q3 2016 and has held it in 4 quarters since. The position peaked at $1.75M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Private Wealth Partners held 360 shares of Regeneron Pharmaceuticals worth $224K as of Q2 2026.
  • Private Wealth Partners sold 1,735 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.18M.
  • Regeneron Pharmaceuticals made up 0.02% of Private Wealth Partners's portfolio in Q2 2026, its #167 holding.
  • Private Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 4 quarters since.
  • Private Wealth Partners's Regeneron Pharmaceuticals position peaked at $1.75M in Q4 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Private Wealth Partners's 13F filing for Q2 2026, filed 3 Aug 2026.